Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD). Patients will be randomized in a 1:1 assignment to receive either oral mycophenolate mofetil (MMF) and a placebo (Plac) or a combination of oral MMF and oral pirfenidone (PFD), with both regimens administered for 18 months. The primary hypothesis is that the rapid onset and anti-fibrotic effects of PFD, which have been observed in the treatment of Idiopathic Pulmonary Fibrosis (IPF), will complement the delayed antiinflammatory and immunosuppressive effects of MMF, to produce a significantly more rapid and/or greater improvement in lung function over time than occurs in patients receiving control therapy with MMF and Plac.
Scleroderma, SystemicInterstitial Lung DiseaseLung DiseasesScleroderma, DiffuseScleroderma, LocalizedLung Diseases, InterstitialMycophenolic AcidPirfenidonePirfenidone (PFD)Mycophenolate Mofetil (MMF)Pirfenidone (PFD) + Mycophenolate (MMF)
You can join if…
Open to people ages 18 years and up
- Age ≥18 yrs
- Scleroderma as determined by the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.
- Grade ≥2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index
- FVC-% of ≤85% at both screening and baseline visits
- Onset of the first non-Raynaud manifestation of SSc within the prior 84 months.
- Presence of any ground-glass opacification (GGO) on thoracic HRCT
- Repeat FVC-% at the baseline visit within 10% of the FVC-% value measured at screening and ≤85%. If these criteria are not met, a repeat FVC-% may be obtained within 7 days and the subject may qualify for randomization if the repeat FVC-% agrees within 10% of the FVC-% obtained at screening.
You CAN'T join if...
- Disease features supporting the primary diagnosis of another connective tissue disease such as rheumatoid arthritis, systemic lupus erythematosus or mixed connective tissue disease (Features consistent with a secondary Sjogren syndrome or scleroderma-associated myopathy will be allowed).
- FVC-% of <45% at either screening or baseline.
- Forced Expiratory Volume in the first second (FEV1)/Forced Vital Capacity (FVC) ratio <0.65 at either screening or baseline.
- DLCOHb-% of <30% at screening or <25% at baseline.
a) All participants with a DLCOHb-% between 30 to 40% must have pulmonary artery pressures documented by either echocardiogram, right heart catheterization or magnetic resonance imaging in order to be considered for inclusion.
- Diagnosis of clinically significant resting pulmonary hypertension requiring treatment as ascertained prior to study evaluation or as part of a standard of care clinical assessment performed outside of the study protocol.
- Evidence of uncontrolled congestive heart failure, unstable ischemic heart disease, history of pulmonary embolism, or cardiac arrhythmia requiring chronic anticoagulation.
- Clinically significant abnormalities on HRCT not attributable to SSc
- Hematologic abnormality at screening including:
Leukopenia (white blood cells [WBC] <4.0x103/µl).
Thrombocytopenia (platelet count <150.0x103/µl).
- Clinically significant anemia [Hemoglobin (Hgb) <10.0 g/dl].
Participants with an identified and correctable etiology may be eligible if repeat testing within the maximal 90-day screening period meets all criteria.
- A diagnosis of chronic liver disease or abnormal baseline liver function test (LFTs) or total bilirubin that are >2.0 x upper normal limit
- . Serum creatinine >2.0mg/dl
- . History of recurrent aspiration, uncontrolled heartburn, or gastroesophageal reflux disease (GERD) with a reflux scale score of >1.00 as determined by a UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Scale (UCLA SCTC GIT), Version 2.0.
Participants with uncontrolled heartburn or GERD that is amenable to medical management may be eligible if repeat testing within the maximal 90-day screening period meets this criteria.
- . Known achalasia, esophageal stricture or esophageal dysfunction sufficient to limit the ability to swallow medication.
- . Pregnancy (as documented by blood test) and/or breast feeding
- . If of child bearing potential (a female participant < 55 years of age who has not been postmenopausal for ≥ 5 years or who has not had a hysterectomy and/or oophorectomy), failure to employ two reliable means of contraception which may include surgical sterilization, barrier methods, spermicidals, intrauterine devices, and/or hormonal contraception, unless the participant chooses abstinence (to avoid heterosexual intercourse completely). If a subject chooses abstinence, then a second reliable means of contraception is not needed.
- . Prior use of potential disease modifying antirheumatic drugs (DMARDs) according to the following exposure rules:
- Use of oral cyclophosphamide (CYC), MMF, azathioprine or other oral or short half-life DMARDs (as detailed in Protocol Section 7.5.1a) for more than 12 weeks in the past six months.
- Treatment with three or more intravenous doses of CYC, Rituximab or other intravenous or injectable DMARDs (as detailed in Protocol Section 7.5.1b) in the past year.
- More distant history of treatment with a DMARD is allowed as long as the patient has a new diagnosis/new episode of active SSc-ILD since stopping that treatment and meets the criteria noted in 15a or 15b. .
- . Use of CYC, MMF, azathioprine, Rituximab or other DMARD (as defined in Protocl Section 7.5.1a&b) in the 30 days prior to their baseline visit unless the patient is on MMF and the responsible physician indicates that continued use s in the best clinical interest of the patient.
- . Active infection (lung, ulcers or elsewhere) whose management would be compromised by immunosuppression.
- . Other serious concomitant medical illness (e.g., active malignancy within the past 5 years other than surgically-removed local skin cancer such as a basal cell carcinoma), chronic debilitating illness (other than SSc), unreliability or drug abuse that might compromise the patient's participation in the trial.
- . Current use, or use within the 30 days prior to their baseline visit, of prednisone (or equivalent) in doses >10 mg/day.
- . Smoking of cigars, pipes, or cigarettes during the past 6 months.
- . Use of contraindicated medications, including medications with putative disease-modifying properties within the past month, moderate or strong inhibitors of cytochrome P450 (CYP) isozyme 1A2 (CYP1A2) (note ciprofloxacin allowed up to a dose of 500 mg twice daily), and moderate inducers of CYP1A2 (such as tobacco smoke, montelukast or phenytoin). See Protocol Section 7.5 for complete list.
- University of California San Franciscoaccepting new patients
San FranciscoCalifornia94143United States
- University of California Los Angelesaccepting new patients
Los AngelesCalifornia90095United States
Lead Scientist at UCSF
- Jeffrey Golden
Authored (or co-authored) 82 research publications
- accepting new patients
- Start Date
- Completion Date
- Michael Roth
- Phase 2
- Study Type
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT03221257.